RayzeBio gets unexpected lift from broad investor appetite for targeted radiotherapies

Encountering unanticipated investor interest after closing its series A round,  RayzeBio followed up two months later with a series B raise that triples its reserves and frees the platform company from the need to make trade-offs between pipeline programs.

The company’s quick jump from a $45 million series A round Oct. 14 to $105 million series B round Dec. 8 reflects growing enthusiasm for targeted radiotherapies. Once left for dead, the field has been revived by clinical and commercial success, including a handful of ten-figure takeouts...